1. Home
  2. AZZ vs BEAM Comparison

AZZ vs BEAM Comparison

Compare AZZ & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AZZ Inc.

AZZ

AZZ Inc.

HOLD

Current Price

$132.77

Market Cap

3.3B

Sector

Industrials

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.55

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZZ
BEAM
Founded
1956
2017
Country
US
US
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
2.7B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
AZZ
BEAM
Price
$132.77
$27.55
Analyst Decision
Buy
Buy
Analyst Count
5
14
Target Price
$118.00
$46.00
AVG Volume (30 Days)
131.5K
1.5M
Earning Date
04-08-2026
04-01-2026
Dividend Yield
0.60%
N/A
EPS Growth
N/A
N/A
EPS
9.97
N/A
Revenue
$1,061,817,000.00
$24,000.00
Revenue This Year
$5.53
N/A
Revenue Next Year
$5.59
$22.06
P/E Ratio
$13.32
N/A
Revenue Growth
14.53
33.33
52 Week Low
$70.90
$13.53
52 Week High
$141.18
$36.44

Technical Indicators

Market Signals
Indicator
AZZ
BEAM
Relative Strength Index (RSI) 60.56 48.18
Support Level $124.97 $26.20
Resistance Level $141.18 $29.26
Average True Range (ATR) 3.63 1.64
MACD 0.23 -0.09
Stochastic Oscillator 54.34 59.33

Price Performance

Historical Comparison
AZZ
BEAM

About AZZ AZZ Inc.

AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: